Literature DB >> 25977907

The clinical characteristics of subependymal giant cell astrocytoma: five cases.

Tae-Young Jung1, Young-Hee Kim1, Shin Jung1, Hee-Jo Baek2, Kyung-Hwa Lee3.   

Abstract

In this study, we reviewed the clinical characteristics of five cases of subependymal giant cell astrocytoma (SEGA) at our hospital between May 1997 and July 2012. The median age was 18 years old (range, 8 to 26). The clinical symptoms were presented as seizure in two patients and headache in three patients. All the tumors were located near the foramen of Monro. The median size of the tumors was 2.5 cm (range, 1.9-4.0). Two patients showed the solitary lesion, and three had subependymal nodules and cortical tubers. The median follow-up duration was 7.4 years (range, 2.0-14.3). Three patients were associated with the tuberous sclerosis complex (TSC). Four patients showed the SEGA at the first presentation and one patient experienced the 1.9 cm-sized growing mass during 7.7 years follow-up after the diagnosis of the TSC. The mass was totally removed in four patients and subtotally in one. Postoperatively, one patient took the medication for the seizure, which was controllable. The subtotally removed mass showed the recurrence postoperative 4.1 years later, and the recurred mass was stable for 4.5 years after the recurrence. The clinical follow-up study of the SEGA showed an indolent behavior before and after the surgery.

Entities:  

Keywords:  Astrocytoma; Follow-up studies; Neurosurgery; Tuberous sclerosis

Year:  2015        PMID: 25977907      PMCID: PMC4426277          DOI: 10.14791/btrt.2015.3.1.44

Source DB:  PubMed          Journal:  Brain Tumor Res Treat        ISSN: 2288-2405


  15 in total

Review 1.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

2.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference.

Authors:  Hope Northrup; Darcy A Krueger
Journal:  Pediatr Neurol       Date:  2013-10       Impact factor: 3.372

3.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

Authors:  Darcy A Krueger; Marguerite M Care; Katherine Holland; Karen Agricola; Cynthia Tudor; Prajakta Mangeshkar; Kimberly A Wilson; Anna Byars; Tarek Sahmoud; David Neal Franz
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

4.  Intraventricular lesions in tuberous sclerosis complex: a possible association with the caudate nucleus.

Authors:  Joel S Katz; Sarah S Milla; Graham C Wiggins; Orrin Devinsky; Howard L Weiner; Jonathan Roth
Journal:  J Neurosurg Pediatr       Date:  2012-04       Impact factor: 2.375

5.  Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature.

Authors:  M E A P M Adriaensen; C M Schaefer-Prokop; T Stijnen; D A C Duyndam; B A Zonnenberg; M Prokop
Journal:  Eur J Neurol       Date:  2009-02-19       Impact factor: 6.089

6.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

Authors:  David Neal Franz; Elena Belousova; Steven Sparagana; E Martina Bebin; Michael Frost; Rachel Kuperman; Olaf Witt; Michael H Kohrman; J Robert Flamini; Joyce Y Wu; Paolo Curatolo; Petrus J de Vries; Vicky H Whittemore; Elizabeth A Thiele; James P Ford; Gaurav Shah; Helene Cauwel; David Lebwohl; Tarek Sahmoud; Sergiusz Jozwiak
Journal:  Lancet       Date:  2012-11-14       Impact factor: 79.321

7.  Causes of death in patients with tuberous sclerosis.

Authors:  C W Shepherd; M R Gomez; J T Lie; C S Crowson
Journal:  Mayo Clin Proc       Date:  1991-08       Impact factor: 7.616

8.  Glioblastoma following radiotherapy in a patient with tuberous sclerosis.

Authors:  H Matsumura; H Takimoto; N Shimada; M Hirata; T Ohnishi; T Hayakawa
Journal:  Neurol Med Chir (Tokyo)       Date:  1998-05       Impact factor: 1.742

9.  Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.

Authors:  Jonathan Roth; E Steve Roach; Ute Bartels; Sergiusz Jóźwiak; Mary Kay Koenig; Howard L Weiner; David N Franz; Henry Z Wang
Journal:  Pediatr Neurol       Date:  2013-10-15       Impact factor: 3.372

Review 10.  Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. Case report and review of literature.

Authors:  Hugo Sterman; Andre Beer Furlan; Hamilton Matushita; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2012-11-09       Impact factor: 1.475

View more
  4 in total

1.  Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.

Authors:  Martine Fohlen; Ines Harzallah; Marc Polivka; Fabienne Giuliano; Linda Pons; Nathalie Streichenberger; Georg Dorfmüller; Renaud Touraine
Journal:  Childs Nerv Syst       Date:  2020-02-26       Impact factor: 1.475

2.  Trends in survival and treatment of SEGA: National Cancer Database Analysis.

Authors:  James S Ryoo; Syed I Khalid; Anisse N Chaker; Mandana Behbahani; Ravi S Nunna; Ankit I Mehta
Journal:  Neurooncol Pract       Date:  2020-09-28

3.  CD99: A potential Diagnostic Marker for Differentiating Sub-ependymal Giant Cell Astrocytoma From Other Mimickers: A Report of Five Cases.

Authors:  Alireza Sadeghipour; Navid Abdi; Pegah Babaheidarian
Journal:  Iran J Pathol       Date:  2017-07-01

4.  Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report.

Authors:  Jae-Young Kim; Tae-Young Jung; Kyung-Hwa Lee; Seul-Kee Kim
Journal:  Brain Tumor Res Treat       Date:  2017-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.